The class 3 semaphorins, sema3A and sema3C, provide important guidance cues in cell development and in cancer; however, the role of these semaphorins in prostate cancer is not known. We report here that sema3A transfected cells exhibit decreased invasion and adhesion in Matrigel-based assays and that sema3C transfected cells exhibit increased invasive and adhesive characteristics. Important adhesion proteins were differentially modulated in sema3A and sema3C cells in a manner consistent with their subsequent invasive and adhesive characteristics. E-cadherin expression as determined by Western blot analysis was strongly upregulated in sema3A transfected cells, but strongly downregulated in sema3C transfected cells compared to untransfected and mock empty vector-transfected PC-3 cells. ß-catenin levels were not changed in sema3A transfected cells; however, sema3C transfected cells had lower expression of this protein. Sema3C transfected cells exhibited greater cellular membrane expression of certain • integrins as compared to untransfected and sema3A transfected cells, a characteristic associated with increased adhesion and invasion. These data indicate that the invasive ability of sema3A and sema3C transfected PC-3 cells is, in part, correlated with adhesion protein expression and adhesive ability to constituents of neighboring cells and the extracellular matrix.
In vitro invasion and adhesion of stably semaphorin (sema) 3E-transfected PC-3 prostate cancer cells were determined in the presence and absence of transferrin. Invasion and adhesion decreased compared to untransfected cells; however, transferrin reversed the effects. Transferrin differentially regulated E-cadherin and ß-catenin in these cells. Insulin growth factor 3 (IGFBP3) negated the invasive and adhesive effects of transferrin. Transferrin increased binding of insulin growth factor (IGF)-1 to the activated IGF-1 receptor, and IGF-1 mimicked the invasive and adhesive effects of transferrin. These data suggest that transferrin modulates sema3E-transfected cells through an IGFBP3/ IGF-1-dependent pathway, in part, by regulation of adhesion proteins.
Abstract. Expression and activity of CC motif ligand 2 (CCL2) is down-regulated by curcumin, the active phytochemical ingredient of turmeric (Curcuma longa), a dietary supplement often self-prescribed to promote prostate health. CCL2 is a potent chemotactic factor of prostate cancer (PCa) with important roles in development of bone metastasis. The relationship between CCL2 and curcumin, however, has not been studied in PCa. Adhesion, invasion and motility of PC-3 cells were measured in response to exposure to curcumin (30 μM; 18 h), CCL2 (100 ng/ml; 18 h) or PMA (100 ng/ml; 18 h). CCL2 mRNA expression and protein secretion levels were measured by real-time PCR and ELISA respectively. Curcumin significantly blocked CCL2 induced adhesion, invasion and motility. Curcumin also significantly suppressed the mRNA expression and secreted CCL2 protein levels. The addition of PMA, a protein kinase C (PKC) activator, blocked the effects of curcumin, leading to an increase in CCL2 expression as well as an increase in PC-3 cell adhesion, invasion and motility. The introduction of a PKC inhibitor, however, blocked the effects of CCL2. We also found that curcumin, CCL2 and PMA, in part, function through the differential regulation of the proteolytic protein matrix metalloproteinase (MMP)-9. These data indicate a potential mechanism; by which curcumin can block the chemotactic effects of CCL2 on PCa. Curcumin exerts potential anti-metastatic effects in bone-derived PCa cells by blocking CCL2 mediated actions on invasion, adhesion and motility, in part through differential regulation of PKC and MMP-9 signaling.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.